Latest Content

Teaching, Writing, Healing: The Intersections of My Cancer Journey

May 24th 2025, 2:00pm

By Linda Cohen

Fifteen years after being diagnosed with small lymphocytic lymphoma, I’ve found healing and meaning in the work I love and the life I’m grateful to live.

True Grit: The Spirit of an Extraordinary Healer

May 23rd 2025, 9:00pm

By Pamela O’Neil,M.S.N.,NP-C,AOCNP

Article

Heather Patenaude, B.S.N., RN, displays the highest level of technical skills necessary to provide compassionate care to her patients.

Uniting Pediatric and Adult Oncologists to Advance AYA Lymphoma Care

May 23rd 2025, 8:00pm

By Dr. Andrew M. Evens

Video

Dr. Andrew M. Evens discusses some of the recent research advancements in AYA lymphoma care that have emerged through clinical trials and initiatives.

Making Something Positive out of Breast Cancer

May 23rd 2025, 7:00pm

By Loraine Alderman

Article

After my breast cancer treatment, I started a clothing bank to give others free access to recovery items like post-surgery shirts and pillows.

Ovarian Cancer Treatment Side Effects Make for a Difficult Balancing Act

May 23rd 2025, 5:00pm

By Kelly Irvin

Article

I urge researchers to look into why side effects occur in cancer drugs and to find ways to mitigate them that doesn’t impact their efficacy.

GLP-1 Drugs Linked to Fewer Obesity-Related Cancers

May 23rd 2025, 3:00pm

By Ariana Pelosci

Article

GLP-1 drugs lowered rates of obesity-related cancers and death versus DPP-4s, with no increased cancer risk, study finds.

Breaking Down Treatment Variables in AYA Patients With Cancer

May 23rd 2025, 1:00pm

By Ryan Scott

Article

Dr. Andrew M. Evens discussed the importance of differentiating AYA cancers from other age groups, specifically focusing on lymphoma care.

Itovebi Triplet Combo Boosts Survival in HR+, HER2– Breast Cancer

May 22nd 2025, 9:00pm

By Caroline Seymour

Article

Itovebi plus Ibrance and Faslodex improved overall survival in patients with PIK3CA-mutant, HR+, HER2–, endocrine-resistant breast cancer versus placebo.

Zepzelca Plus Tecentriq Boosts Survival in First-Line ES-SCLC Care

May 22nd 2025, 9:00pm

By Kristi Rosa

Article

Among patients with ES-SCLC, first-line maintenance therapy with Zepzelca plus Tecentriq led to improvements in PFS and OS versus Tecentriq alone.

Expert Offers Surveillance, Lifestyle Guidance After CRC, Anal Cancer

May 22nd 2025, 7:00pm

By Dr Rebecca Rhee

Video

Avoiding smoking, eating a high-fiber diet and routine screenings are key to reducing the risk of recurrence in colorectal or anal cancer.

Contemplating AI Assistance as a Cancer Survivor

May 22nd 2025, 5:00pm

By Felicia Mitchell

Article

When I saw a study about using AI facial recognition in cancer decision-making headlines, I decided to try my own informal, non-scientific experiment.